GATA17 Antibody
Description
GATA-1 Antibodies
GATA-1 is a transcription factor critical for hematopoiesis, particularly erythropoiesis. Antibodies targeting GATA-1 are widely used in research and diagnostics.
Key Applications:
-
Western blotting: Detects GATA-1 in lysates of human leukemia cell lines (e.g., K562) with high specificity (~50 kDa band observed) .
-
Flow cytometry: Enables intracellular detection in human cell lines (e.g., MCF-7 breast cancer cells) after fixation and permeabilization .
-
Cross-reactivity: Minimal (<1%) with related GATA family members (e.g., GATA-2, GATA-5, GATA-6) .
17-1A Monoclonal Antibody
The 17-1A monoclonal antibody (MAb) targets a 37 kDa epithelial cell surface antigen (17-1A Ag), which is overexpressed in colorectal and gastric carcinomas .
Research Findings:
-
Therapeutic use: Evaluated in immunotherapy trials for colorectal cancer .
-
Epitope diversity: Multiple MAbs (e.g., M72, M74, M77, M79) recognize distinct epitopes on the 17-1A antigen, enabling combination therapies .
-
Normal tissue expression: Found in healthy epithelial tissues but quantitatively elevated in malignancies .
Anti-Gastrin Antibodies (G17-DT)
While unrelated to GATA-1 or 17-1A, G17-DT is a gastrin-17-diphtheria toxoid immunogen that induces high-affinity anti-gastrin antibodies. These antibodies neutralize gastrin, a growth factor for colorectal cancer, and were tested in Phase I/II trials .
Clinical Data:
Antibody Isotypes and Functions
Antibody isotypes (e.g., IgG, IgA) determine effector functions. For example:
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Based on analysis of peer-reviewed literature and patents, the term "GATA17 Antibody" appears to involve potential terminology confusion between transcription factor GATA3's role in Th17 cell regulation and gastrin-17 (G17) detection methodologies. Below are structured FAQs addressing both research contexts with technical precision:
How do Th17 cell dynamics influence antibody validation in autoimmune models?
Key Findings:
-
GATA3 expression peaks at day 4 post-immunization in EAE models, correlating with T-bet+RORγt+ Th17 pathogenicity
-
Conditional GATA3 deletion reduces GM-CSF production by 62% (p<0.001) and EAE clinical scores by 4.2-fold
RosettaAntibodyDesign (RAbD) Workflow:
-
Graft CDRs from canonical clusters using structural bioinformatics
-
Apply risk ratio analysis:
-
Achieved 10-50x affinity improvements through strategic mutations (e.g., Y38K in CDR-L1)
Thermostability Comparison:
| Antibody Variant | Tm (°C) Major Peak | ΔAffinity (nM) |
|---|---|---|
| Wild Type | 75.0 | 14.2 |
| L14_7 Design | 71.9 | 4.3 |
How to resolve contradictory results in Th17/antibody co-activation studies?
Case Analysis:
-
Observation: Th17-neutrophil axis enhances mucosal GAS clearance but shows limited systemic protection
-
Resolution Strategy:
Statistical Framework:
What quality controls are essential for clinical-grade anti-IL17A antibodies?
Critical Parameters:
-
Neutralization potency: IC50 ≤0.5 nM in HFF-1 IL6 inhibition assays
-
Epitope mapping: Target IL17A C-terminal ridge (validated by SPR with KD≤100 pM)
Batch Consistency Metrics:
| Test | Acceptance Criteria |
|---|---|
| Charge Variants | ≤5% acidic/basic species |
| Aggregation | <1.0% by SEC-MALS |
| Glycan Profile | ≤10% afucosylation |
